Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 12/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | PTPRA | P18433 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 2/20 | 0.41 |
| ▸ | CTSB | P07858 | 2/20 | 0.41 |
| ▸ | CTSS | P25774 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28916941 | 0.86 | ALDH1A1 (0.43) | CTSKATMPTPRAHDAC6CTSL | |
| SCHEMBL30850109 | 0.83 | POLB (0.46) | CTSKATMPTPRAHDAC6HDAC1 | |
| SCHEMBL13349692 | 0.81 | PTPRA (0.42) | CTSKPTPRAHDAC6HDAC1CTSL | |
| SCHEMBL7862733 | 0.81 | PTPRA (0.49) | ATMPTPRAHDAC6HDAC1CYP1A2 | |
| SCHEMBL27264324 | 0.81 | PTPRA (0.49) | ATMPTPRAHDAC6HDAC1CYP1A2 | |
| SCHEMBL7863671 | 0.81 | PTPRA (0.49) | ATMPTPRAHDAC6HDAC1CYP1A2 | |
| SCHEMBL215178 | 0.81 | ACE (0.56) | CTSKPTPRAHDAC6HDAC1CTSL | |
| SCHEMBL215179 | 0.81 | ACE (0.56) | CTSKPTPRAHDAC6HDAC1CTSL | |
| SCHEMBL268002 | 0.81 | ACE (0.56) | CTSKPTPRAHDAC6HDAC1CTSL | |
| SCHEMBL22559221 | 0.81 | ATM (0.48) | CTSKATMPTPRAHDAC6HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144681-A1 | COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BOEHRINGER INGELHEIM INTERNATION GMNB (DE) | 2010-06-10 | — | — | US | disclosed |
| EP-1347990-A2 | PEPTIDE MIT INHIBIERENDER AKTIVITÄT ZUR PRODUKTION VON STICKSTOFFMONOXID | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-10-01 | — | — | EP | disclosed |
| WO-2002055541-A2 | PEPTIDES HAVING INHIBITING ACTIVITY ON THE PRODUCTION OF NITRIC OXIDE | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144681-A1 | COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | PSEN1, PSEN2, ADORA3 | CTSK 1858/4885ATM 1918/4885PTPRA 3318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.